Survival with Osimertinib plus Chemotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutated Advanced NSCLC
AstraZeneca
Pasi A Jänne; David Planchard; Kunihiko Kobayashi; James Chih-Hsin Yang; Ying Liu; Natalia Valdiviezo; Tae Min Kim; Liyan Jiang; Hiroshi Kagamu; Noriko Yanagitani; Jialei Wang; Bivas Biswas; Artem Poltoratskiy; Yeni Neron; Carlos Rojas; Leona Koubkova; Carles Escriu; Doreen A Ezeife; Helen Mann; Elena Armenteros-Monterroso; Yuri Rukazenkov; Chee Khoon Lee; FLAURA2 Investigators
Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.